Screener
Apogee Therapeutics, Inc. APGE Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Apogee Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: Apogee Therapeutics, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 7:20 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-215698
| Line item | THREE MONTHS ENDED MARCH 31, 2026 | THREE MONTHS ENDED MARCH 31, 2025 |
|---|---|---|
| Proceeds from issuance of common stock, net of issuance costs | 378,169 | — |
| Proceeds from issuance of common stock under the ATM Facility, net of issuance costs | 28,934 | — |
| Proceeds from exercise of options | 4,064 | 622 |
| Net cash provided by financing activities | 411,167 | 622 |
| Increase (decrease) in cash, cash equivalents and restricted cash | 320,248 | (34,873) |
| Cash, cash equivalents and restricted cash, beginning of period | 131,549 | 142,083 |
| Cash, cash equivalents and restricted cash, end of period | $451,797 | $107,210 |
| Supplemental disclosures of non-cash activities: |
Item 6. [Exhibits](#item_6_exhibits) [71](#item_6_exhibits)
FAQ
- What is Apogee Therapeutics, Inc.'s financing cash flow?
- Apogee Therapeutics, Inc. (APGE) reported financing cash flow of $411.17M in Q1 2026.
- How has Apogee Therapeutics, Inc.'s financing cash flow changed year-over-year?
- Apogee Therapeutics, Inc.'s financing cash flow increased by 66004.0% year-over-year, from $622K to $411.17M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about Apogee Therapeutics, Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude